Vas Narasimhan, Novartis CEO (Jason Alden/Bloomberg via Getty Images)
October 28, 2021 07:18 AM EDTUpdated 09:09 AM
Pharma

No­var­tis in hot wa­ter again over al­leged kick­backs, re­veal­ing new DoJ probe re­lat­ed to En­tresto

Max Gelman

Senior Editor

No­var­tis’ En­tresto has proven a block­buster drug since its ap­proval in 2015, net­ting $924 mil­lion in sales this past quar­ter alone, rep­re­sent­ing a 46% gain …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

In­cyte touts Mon­ju­vi da­ta from Phase 3 fol­lic­u­lar lym­phoma tri­al as it heads to FDA

Cas­sa­va shares plunge as con­tro­ver­sial Alzheimer’s drug fails Phase 3 tri­al

Bris­tol My­ers re­veals more job cuts in New Jer­sey

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

Trump taps Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, sur­geon gen­er­al picks

A service from the Financial Times